Application of a nanocomplex technology to the active permeation of the blood brain barrier (BBB)
Ended Definitive Contract Awarded Last action
- Contract number
- HDTRA120C0045
- Awardee
-
Synergene Therapeutics Inc. UEI W8E3G5851JK4
- Awarding agency
-
Defense Threat Reduction Agency
Department of Defense
- Obligated
- $7,589,344
Award facts
- Opportunity
-
- HDTRA119R0026 Solicitation number
- Contract value 62% obligated
-
- $7,589,343.79 Current, with exercised options
- $12,202,250.58 Potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- Total Small Business
- Competition
- Full and Open Competition after exclusion of sources · 1 offer Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Potomac, MD 20854, USA
- Research
- STTR Phase III
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | $706,655 | |
| Exercise an Option | $784,691 | |
| Funding Only Action | $688,894 | |
| Funding Only Action | $100,000 | |
| Supplemental Agreement for work within scope | $50,104 | |
| Exercise an Option | $600,000 | |
| Supplemental Agreement for work within scope | $0 | |
| Funding Only Action | $735,092 | |
| Additional Work (new agreement, FAR part 6 applies) | $772,668 | |
| Funding Only Action | $700,000 | |
| Funding Only Action | $1,107,693 | |
| Funding Only Action | $343,548 | |
| Original award | $1,000,000 |
Show all 13
About this award
The U.S. Defense Threat Reduction Agency (DTRA) awarded a $12,202,250.58 Cost Plus Fixed Fee contract to Synergene Therapeutics Inc., a small business, for the application of a nanocomplex technology to the active permeation of the blood-brain barrier (BBB). This is a Definitive Contract, and the ultimate completion date is July 6, 2025. The contract is a Small Business Set Aside and was awarded on July 7, 2020 under the STTR Phase III research program.
Quick answers
Who was awarded contract HDTRA120C0045?
HDTRA120C0045 was awarded to Synergene Therapeutics Inc. by Defense Threat Reduction Agency (Department of Defense) on July 7, 2020.
How much is contract HDTRA120C0045 worth?
The government has obligated $7,589,344 on HDTRA120C0045. Its potential value, with all options, is $12,202,251.
Was contract HDTRA120C0045 competed?
The extent of competition for HDTRA120C0045 was full and open competition after exclusion of sources. The government received 1 offer. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award